The Senate Finance Committee today held a hearing for Alex Azar, President Trump’s nominee for secretary of Health and Human Services. Azar, former president of Lilly USA and deputy HHS secretary under the George W. Bush administration, faced a number of questions from senators about his ties to the pharmaceutical industry and how he would tackle high drug prices. If confirmed, Azar said he would focus his efforts on addressing the high cost of drugs; making health care more affordable, available and “tailored to what individuals want and need in their care”; harnessing “the power of Medicare to shift the focus in our health care system from paying for procedures and sickness to paying for health and outcomes”; and tackling “the scourge of the opioid epidemic.” Tom Price, M.D., resigned as HHS secretary last September. Deputy Secretary Eric Hargan has been serving as acting secretary.

Related News Articles

Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
The House Ways and Means Committee today launched a health task force to better address the needs of residents in rural and underserved communities.
Headline
Under a new Centers for Medicare…
Headline
Updated guidance issued last year for states seeking a Section 1332 waiver of certain Affordable Care Act requirements qualifies as a rule under the…
Headline
The Centers for Medicare…
Headline
The House Energy and Commerce Subcommittee on Health today passed the No Surprises Act (H.R. 3630), bipartisan legislation that would prohibit balance billing…